Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Total Liabilities: 2009-2024

Historic Total Liabilities for Gyre Therapeutics (GYRE) over the last 15 years, with Dec 2024 value amounting to $27.0 million.

  • Gyre Therapeutics' Total Liabilities fell 17.92% to $22.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.0 million, marking a year-over-year decrease of 17.92%. This contributed to the annual value of $27.0 million for FY2024, which is 29.06% down from last year.
  • According to the latest figures from FY2024, Gyre Therapeutics' Total Liabilities is $27.0 million, which was down 29.06% from $38.1 million recorded in FY2023.
  • Gyre Therapeutics' 5-year Total Liabilities high stood at $38.1 million for FY2023, and its period low was $12.5 million during FY2022.
  • Over the past 3 years, Gyre Therapeutics' median Total Liabilities value was $27.0 million (recorded in 2024), while the average stood at $25.9 million.
  • Per our database at Business Quant, Gyre Therapeutics' Total Liabilities soared by 203.65% in 2023 and then declined by 29.06% in 2024.
  • Gyre Therapeutics' Total Liabilities (Yearly) stood at $18.8 million in 2020, then dropped by 22.39% to $14.6 million in 2021, then dropped by 13.98% to $12.5 million in 2022, then skyrocketed by 203.65% to $38.1 million in 2023, then declined by 29.06% to $27.0 million in 2024.